Mahmoud Okasha
Psychiatry · Norwich, CTNPI 1083890016
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,743 of the $20,149 with a category attached, or 73.2%. AbbVie accounts for 80.5% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2021 at $8,081 and has fallen 99.5% since, to $38 in 2024. Among psychiatry clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 342 payments — averaging $58.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$16K
- Takeda Pharmaceuticals U.S.A., Inc.$618
- Lundbeck LLC$580
- Johnson & Johnson$385
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$355
- Otsuka America Pharmaceutical, Inc.$343
- plus $2K from 17 others
Across 279 payments — averaging $5119.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$817K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$419K
- Biohaven Pharmaceutical Holding Company Ltd.$123K
- AbbVie$29K
- Biohaven Pharmaceuticals, Inc.$21K
- Amgen$15K
- plus $6K from 1 others
What the payments were for
- Speaking & faculty fees$14,74373%
- Food & beverage$5,29926%
- Education$1071%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 125 | $16,215 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $618 |
| Lundbeck LLC | 32 | $580 |
| Johnson & Johnson | 22 | $385 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $355 |
| Otsuka America Pharmaceutical, Inc. | 18 | $343 |
| Vanda Pharmaceuticals Inc. | 16 | $297 |
| Neurocrine Biosciences, Inc. | 15 | $289 |
| Supernus Pharmaceuticals, Inc. | 10 | $168 |
| Sunovion Pharmaceuticals Inc. | 12 | $163 |
| Jazz Pharmaceuticals Inc. | 5 | $120 |
| Alkermes, Inc. | 6 | $108 |
| Eisai Inc. | 5 | $84 |
| Ironshore Pharmaceuticals Inc. | 4 | $80 |
| Teva Pharmaceuticals USA, Inc. | 4 | $77 |
| Shire North American Group Inc | 4 | $64 |
| Adlon Therapeutics L.p. | 3 | $54 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| Avanir Pharmaceuticals, Inc. | 2 | $32 |
| Bausch Health US, LLC | 2 | $29 |
| Corium, LLC | 1 | $23 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$14,860
How this compares
$20,149 in reported general payments places this provider in the 95th percentile of 644 psychiatry providers in Connecticut.
Other psychiatry in Norwich
- Kelly JaziriNorwich$21K
- Walid JaziriNorwich$17K
- Vladimir CoricNew Haven$133.7M
- Donald AmmermanDanbury$1.5M
- Joseph GoldbergNew Canaan$914K
- Lisa HardingMilford$608K
- Tarique PereraDanbury$383K
- John GelinasDanbury$364K
- Irene AbramovichWest Hartford$352K
- Robert BermanNew Haven$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.